BioCryst Pharmaceuticals vs Neurocrine Biosciences
BCRX and NBIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCRX and NBIX compare
Neurocrine Biosciences is the larger company, worth 6.9 times as much as BioCryst Pharmaceuticals ($14.9B against $2.2B).
BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus 34.4% for Neurocrine Biosciences).
Neurocrine Biosciences keeps more of each dollar of sales as profit, with a net margin of 20.9% compared with −40.9% at BioCryst Pharmaceuticals.
Neurocrine Biosciences scores higher on the StockData Score (19 against 9 for BioCryst Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCRX | NBIX |
|---|---|---|
| Size and price | ||
| Market cap | $2.2B | $14.9B |
| Share price | $8.47 | $146.10 |
| Change, 1 year | 15.9% | 5.9% |
| Change, 5 years | −31.7% | 56.7% |
| Beta (5Y) | 0.80 | 0.49 |
| Employees | 435 | 1,800 |
| StockData Score | ||
| Total score | 9 | 19 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 4 | 5 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 21.4× |
| P/S | 2.3× (better) | 4.4× |
| P/B | – | 4.0× |
| EV/EBITDA | – | 18.2× |
| P/FCF | 5.8× (better) | 17.1× |
| PEG | – | 0.49 |
| FCF yield | 17.3% (better) | 5.9% |
| Fair value | – | $177.51 |
| Margin of safety | – | 17.7% |
| Growth | ||
| Revenue growth (TTM) | 68.7% (better) | 34.4% |
| Revenue growth, 5Y average | 118% (better) | 22.3% |
| Net income growth (TTM) | – | 103% |
| EPS growth (TTM) | – | 102% |
| EPS growth, 5Y average | – | 2.3% |
| Profitability | ||
| Gross margin | 97.8% | 98.0% (better) |
| Operating margin | −33.3% | 23.6% (better) |
| Net margin | −40.9% | 20.9% (better) |
| FCF margin | 39.7% (better) | 25.8% |
| Return on equity | – | 22.1% |
| Return on invested capital | – | 23.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −4.2× | – |
| Current ratio | 2.32 (better) | 1.87 |
| Altman Z-score | −3.68 | 6.83 (better) |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.84% |
| Shareholder yield | 0.00% (better) | −0.84% |
| Ownership | ||
| Held by institutions | 103% | 99.5% |
| Held by insiders | 1.9% | 1.2% |
| Insider net buying, 12 months | −$4.1M (better) | −$77.9M |
| Short interest, % of float | 11.0% | 5.8% |
Go deeper
- BCRX stock overview
- BCRX income statement
- BCRX valuation and score
- NBIX stock overview
- NBIX income statement
- NBIX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.